Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study
File(s)PIIS2214109X16301309.pdf (460.21 KB)
Published version
Author(s)
Type
Journal Article
Abstract
Background
Despite the introduction of immunisation for hepatitis B virus (HBV) in the 1990s, HBV-related morbidity and mortality remain high in sub-Saharan Africa. Identification and treatment of asymptomatic people with chronic HBV infection should reduce the disease burden. We therefore assessed the feasibility of a screen-and-treat programme for HBV infection in The Gambia, west Africa, and estimated the proportion of HBV-infected people who had significant liver disease in need of treatment.
Methods
Between Dec 7, 2011, and Jan 24, 2014, individuals living in randomly selected communities in western Gambia were offered hepatitis B surface antigen (HBsAg) screening via a point-of-care test. The test was also offered to potential blood donors attending the central hospital in the capital, Banjul. HBsAg-positive individuals were invited for a comprehensive liver assessment and were offered treatment according to international guidelines. We defined linkage to care as visiting the liver clinic at least once. Eligibility for treatment was judged in accordance with the 2012 European Association for the Study of the Liver guidelines.
Findings
HBsAg screening was accepted by 5980 (weighted estimate 68·9%, 95% CI 65·0–72·4) of 8170 adults from 27 rural and 27 urban communities and 5559 (81·4%, 80·4–82·3) of 6832 blood donors. HBsAg was detected in 495 (8·8%, 7·9–9·7) individuals in communities and 721 (13·0%, 12·1–13·9) blood donors. Prevalence was higher in men (239 [10·5%, 8·9–12·1] of 2328 men vs 256 [7·6%, 6·5–8·7] of 3652 women; p=0·004) and middle-aged participants. Linkage to care was high in the communities, with 402 (81·3%) of 495 HBsAg-positive individuals attending the clinic. However, only 300 (41·6%) of 721 HBsAg-positive people screened at the blood bank linked into care. Of those who attended the clinic, 18 (4·4%, 2·5–7·7) patients from the communities and 29 (9·7%, 6·8–13·6) from the blood bank were eligible for treatment. Male sex was strongly associated with treatment eligibility (odds ratio 4·35, 1·50–12·58; p=0·007).
Interpretation
HBV infection remains highly prevalent in The Gambia. The high coverage of community-based screening, good linkage into care, and the small proportion of HBsAg carriers who need treatment suggest that large-scale screening and treatment programmes are feasible in sub-Saharan Africa.
Despite the introduction of immunisation for hepatitis B virus (HBV) in the 1990s, HBV-related morbidity and mortality remain high in sub-Saharan Africa. Identification and treatment of asymptomatic people with chronic HBV infection should reduce the disease burden. We therefore assessed the feasibility of a screen-and-treat programme for HBV infection in The Gambia, west Africa, and estimated the proportion of HBV-infected people who had significant liver disease in need of treatment.
Methods
Between Dec 7, 2011, and Jan 24, 2014, individuals living in randomly selected communities in western Gambia were offered hepatitis B surface antigen (HBsAg) screening via a point-of-care test. The test was also offered to potential blood donors attending the central hospital in the capital, Banjul. HBsAg-positive individuals were invited for a comprehensive liver assessment and were offered treatment according to international guidelines. We defined linkage to care as visiting the liver clinic at least once. Eligibility for treatment was judged in accordance with the 2012 European Association for the Study of the Liver guidelines.
Findings
HBsAg screening was accepted by 5980 (weighted estimate 68·9%, 95% CI 65·0–72·4) of 8170 adults from 27 rural and 27 urban communities and 5559 (81·4%, 80·4–82·3) of 6832 blood donors. HBsAg was detected in 495 (8·8%, 7·9–9·7) individuals in communities and 721 (13·0%, 12·1–13·9) blood donors. Prevalence was higher in men (239 [10·5%, 8·9–12·1] of 2328 men vs 256 [7·6%, 6·5–8·7] of 3652 women; p=0·004) and middle-aged participants. Linkage to care was high in the communities, with 402 (81·3%) of 495 HBsAg-positive individuals attending the clinic. However, only 300 (41·6%) of 721 HBsAg-positive people screened at the blood bank linked into care. Of those who attended the clinic, 18 (4·4%, 2·5–7·7) patients from the communities and 29 (9·7%, 6·8–13·6) from the blood bank were eligible for treatment. Male sex was strongly associated with treatment eligibility (odds ratio 4·35, 1·50–12·58; p=0·007).
Interpretation
HBV infection remains highly prevalent in The Gambia. The high coverage of community-based screening, good linkage into care, and the small proportion of HBsAg carriers who need treatment suggest that large-scale screening and treatment programmes are feasible in sub-Saharan Africa.
Date Issued
2016-08-01
Date Acceptance
2016-06-07
Citation
Lancet Global Health, 2016, 4 (8), pp.e559-e567
ISSN
2214-109X
Publisher
Elsevier
Start Page
e559
End Page
e567
Journal / Book Title
Lancet Global Health
Volume
4
Issue
8
Copyright Statement
© 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.
License URL
Sponsor
Gilead Sciences Inc
Imperial College Trust
Commission of the European Communities
Wellcome Trust
Imperial College Healthcare NHS Trust- BRC Funding
Medical Research Council (MRC)
Grant Number
n/a
N/A
265994
097816/Z/11/ZR
RDA15 79560
MR/L002086/1
Subjects
Science & Technology
Life Sciences & Biomedicine
Public, Environmental & Occupational Health
SUB-SAHARAN AFRICA
COMMUNITY
PREVALENCE
SETTINGS
CARE
EPIDEMIOLOGY
VACCINATION
PROTECTION
CARRIAGE
CRITERIA
Adult
Age Factors
Antiviral Agents
Blood Donors
Communicable Diseases
Feasibility Studies
Female
Gambia
Hepatitis B
Hepatitis B Surface Antigens
Hepatitis B virus
Humans
Liver Cirrhosis
Male
Mass Screening
Middle Aged
Point-of-Care Systems
Prevalence
Sex Factors
PROLIFICA investigators
Humans
Hepatitis B virus
Communicable Diseases
Hepatitis B
Liver Cirrhosis
Hepatitis B Surface Antigens
Antiviral Agents
Mass Screening
Prevalence
Feasibility Studies
Age Factors
Sex Factors
Adult
Middle Aged
Blood Donors
Point-of-Care Systems
Gambia
Female
Male
0605 Microbiology
1117 Public Health and Health Services
Publication Status
Published
Date Publish Online
2016-07-19